Tevogen Bio Holdings (TVGN) Operating Expenses (2022 - 2026)

Tevogen Bio Holdings has reported Operating Expenses for 5 years, with the latest figure at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 47.85% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $21.2 million (down 38.42% YoY), and the FY2025 full-year result was $26.1 million, down 51.2% from the prior year.
• Operating Expenses for Q1 2026 stood at $5.4 million, up from $4.6 million in the prior quarter.
• The five-year high for Operating Expenses was $29.5 million in Q1 2024, with the low at $198832.0 in Q3 2022.
• Historically, Operating Expenses has averaged $5.6 million across 5 years, with a median of $4.6 million in 2025.
• Annual changes were most pronounced in 2024 — Operating Expenses surged 1169.93% — and 2025, when it slumped 64.91%.
• Tevogen Bio Holdings' Operating Expenses stood at $212787.0 in 2022, then jumped by 844.26% to $2.0 million in 2023, then soared by 366.0% to $9.4 million in 2024, then tumbled by 50.76% to $4.6 million in 2025, then grew by 17.15% to $5.4 million in 2026.
• The last three Operating Expenses figures came in at $5.4 million (Q1 2026), $4.6 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.